University of Oulu
Oulu University Library
OuluCRIS
Laturi
Muuntaja

Similar Items

Cover Image

Puhakka, I., Kuitunen, H., Jäkälä, P. et al. Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis. BMC Cancer 22, 236 (2022). https://doi.org/10.1186/s12885-022-09315-8

Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis

Saved in:
Author: Puhakka, Inka1; Kuitunen, Hanne2; Jäkälä, Pekka1,3;
Organizations: 1Department of Neurology, Kuopio University Hospital, PL 100, 70029, Kuopio, KYS, Finland
2Department of Oncology, University of Oulu, Oulu University Hospital, Kajaanintie 50, 90220, Oulu, Finland
3School of Medicine, Institute of Clinical Medicine, Neurology, University of Eastern Finland Faculty of Medicine, Kuopio, Finland
4Department of Anesthesiology, University of Oulu, Oulu University Hospital, Kajaanintie 50, 90220, Oulu, Finland
5Department of Oncology, Kuopio University Hospital, PL 100, 70029, Kuopio, KYS, Finland
6Kuopio University Hospital, Science Service Center, PL 100, 70029, Kuopio, KYS, Finland
7School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland Faculty of Medicine, Kuopio, Finland
8Department of Oncology and Radiotherapy, Kuopio University Hospital, PL 100, 70029, Kuopio, KYS, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 1 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2022051836434
Language: English
Published: Springer Nature, 2022
Publish Date: 2022-05-18
Description:

Abstract

Background: We report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland.

Methods: Finnish Cancer Registry data by histological diagnosis and tumor location (2007–2017) for cases with diffuse large B-cell lymphoma.

Results: During 2007–2017, 392 new cases of PCNSL were reported (195 males, 197 females). The average age-adjusted incidence was 0.68/100,000 person-years. Incidence for males was 0.74/100,000 and for females 0.63/100,000, respectively. The incidence was highest, 2.93/100,000, among people aged 75–79 years. Concerning all cases in 2007–2017 the 2-year age-adjusted relative survival rate was 33% and the corresponding 5-year survival rate was 26%. Among patients under the age of 70, the age-adjusted 5-year relative survival rate increased from 36% in 2007–2012 to 43% for 2013–2017. Among patients aged 70+ the corresponding survival rates were poor, 7 and 9%.

Conclusions: PCNSL incidence in Finland is among the highest reported in the world. The annual increase in incidence was 2.4%. The prognosis is still dismal, especially in elderly patients.

see all
Series: BMC cancer
ISSN: 1471-2407
ISSN-E: 1471-2407
ISSN-L: 1471-2407
Volume: 22
Article number: 236
DOI: 10.1186/s12885-022-09315-8
OADOI: https://oadoi.org/10.1186/s12885-022-09315-8
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
Article
Funding: The data were received from the FCR without any costs. Partial financial support was received from Pohjois-Suomen terveydenhuollon tukisäätiö (TERTTU foundation) [39] for the preparation of the article. It did not have any role in study design, collection or analysis of the data, writing of the report or the decision to submit the article for publication.
Copyright information: © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
  https://creativecommons.org/licenses/by/4.0/